+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Retinal Vein Occlusion Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 73 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6069458
The global market for Retinal Vein Occlusion Treatment was estimated at US$2.8 Billion in 2024 and is projected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Retinal Vein Occlusion Treatment market.

Global Retinal Vein Occlusion Treatment Market - Key Trends & Drivers Summarized

Why Is Effective Retinal Vein Occlusion (RVO) Treatment Becoming More Important?

Retinal vein occlusion (RVO) is a leading cause of vision impairment, often associated with underlying conditions such as hypertension, diabetes, and cardiovascular diseases. As RVO can lead to severe complications, including macular edema and neovascular glaucoma, the demand for effective treatment strategies has increased. Advances in pharmacotherapy, laser therapy, and surgical interventions have improved patient outcomes, helping to prevent further vision deterioration. The growing aging population, along with the increasing prevalence of metabolic disorders, has contributed to a rise in RVO cases worldwide. As a result, healthcare providers and researchers are focusing on developing more targeted and long-lasting treatment options.

How Are Technological Advancements Improving RVO Treatment Outcomes?

The development of anti-VEGF (vascular endothelial growth factor) therapy has transformed the treatment landscape for RVO-related macular edema, significantly reducing retinal swelling and improving visual acuity. Sustained-release corticosteroid implants have also been introduced, offering long-term benefits with fewer injections. Additionally, advancements in laser photocoagulation techniques, including micropulse laser therapy, have provided more precise treatment options with reduced side effects. AI-powered diagnostic tools and retinal imaging systems are enhancing early detection and personalized treatment planning, ensuring timely interventions for RVO patients. Moreover, emerging regenerative medicine approaches, including stem cell therapy, hold promise for restoring damaged retinal tissues and improving long-term prognosis.

What Market Trends Are Driving the Demand for RVO Treatments?

The increasing adoption of combination therapies, integrating anti-VEGF injections with laser treatments, has enhanced treatment efficacy while reducing the frequency of medical interventions. The expansion of teleophthalmology services has facilitated early diagnosis and remote monitoring, improving patient management. Additionally, the rise of home-based vision monitoring solutions, such as smartphone-based retinal imaging, is empowering patients to track their eye health and seek timely medical attention. Government-funded retinal disease screening programs and healthcare reimbursement policies are further driving market growth. As research continues to explore novel therapeutic approaches, including gene therapy and neuroprotection, the RVO treatment market is evolving rapidly.

What Are the Key Growth Drivers of the RVO Treatment Market?

The growth in the global retinal vein occlusion treatment market is driven by increasing incidences of diabetes and hypertension, advancements in pharmacological therapies, and improvements in retinal imaging technology. The widespread adoption of anti-VEGF therapy as a first-line treatment for RVO-related complications has significantly contributed to market expansion. Additionally, the growing availability of long-acting drug delivery systems is improving patient compliance and reducing treatment burden. The expansion of healthcare access in emerging markets, along with government-led initiatives for vision care, is further accelerating demand. As new therapeutic innovations continue to emerge, the RVO treatment market is expected to witness sustained growth, offering improved solutions for patients worldwide.

Scope of Study:

The report analyzes the Retinal Vein Occlusion Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
  • Segments: Disease Type (Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion); Treatment (Anti-vascular Endothelial Factor, Corticosteroid Drugs, Others); End-Use (Hospital & Clinics, Retail Pharmacy, Others)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Central Retinal Vein Occlusion segment, which is expected to reach US$2.9 Billion by 2030 with a CAGR of a 6.9%. The Branch Retinal Vein Occlusion segment is also set to grow at 4.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $749.4 Million in 2024, and China, forecasted to grow at an impressive 9.7% CAGR to reach $804.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Retinal Vein Occlusion Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Retinal Vein Occlusion Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Retinal Vein Occlusion Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Annexin Pharmaceuticals AB, Bayer AG and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 43 companies featured in this Retinal Vein Occlusion Treatment market report include:

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Retinal Vein Occlusion Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Growing Prevalence of Hypertension and Cardiovascular Risk Factors Drives Incidence of Retinal Vein Occlusion
  • Rising Demand for Anti-VEGF and Corticosteroid Injections Throws the Spotlight on Pharmacologic Management
  • Expansion of Patient Access to Intravitreal Therapies Strengthens Business Case for RVO Treatment Portfolios
  • Development of Sustained-Release Implants Enhances Adherence and Reduces Treatment Burden
  • Clinical Research on Combination Therapies Propels Innovation in Managing Complex and Resistant RVO Cases
  • Integration of OCT Imaging and Angiography in Diagnostic Pathways Enhances Early Detection and Monitoring
  • Rising Emphasis on Personalized Therapy Selection Based on Occlusion Type Supports Precision Medicine Approaches
  • Increased Awareness Campaigns Around Ocular Stroke and Vascular Health Drives Early Intervention Rates
  • Regulatory Approvals for Long-Acting Formulations and New Drug Classes Expand Therapeutic Options
  • Expansion of Ophthalmology Clinics and Ambulatory Injection Facilities Accelerates Market Accessibility
  • Technological Advancements in Intraocular Injection Devices Improve Accuracy and Reduce Complications
  • Growing Pipeline of Novel Biologics and Biosimilars Enhances Competitive Landscape and Affordability
  • Inclusion of RVO Treatment in Public Health Eye Screening Programs Broadens Patient Outreach
  • Use of Adjunctive Laser Therapy in Ischemic RVO Supports Multimodal Treatment Strategies
  • Rising Research on Inflammation and Microvascular Involvement Spurs New Mechanism-Targeted Drugs
  • Shift Toward Evidence-Based Retreatment Protocols Improves Long-Term Visual Outcomes
  • Strategic Collaborations Between Pharma Companies and Retinal Specialists Drive Drug Adoption
  • Real-World Data and Clinical Registries Strengthen Post-Market Evidence for RVO Therapies
  • Reimbursement Expansion and Tiered Access Pricing Models Boost Treatment Uptake in Developing Regions
  • Global Burden of Vision Loss From RVO Accelerates Innovation in Both Diagnostic and Therapeutic Modalities
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Retinal Vein Occlusion Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Central Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Branch Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Anti-vascular Endothelial Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • CANADA
  • JAPAN
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • CHINA
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • EUROPE
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • FRANCE
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • GERMANY
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • ITALY
  • UNITED KINGDOM
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • AUSTRALIA
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • INDIA
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

Table Information